TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15319604

Group type: EXPERIMENTAL
Intervention: 99mTc ethylene dicysteine (99mTc‐EC)
Number of subjects: 43

Group type: COMPARATOR
Intervention: 99mTc dimercaptosuccinic acid (99mTc‐DMSA)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Differential renal function measurements
Number of subjects: 43
Study: 10866903

Group type: EXPERIMENTAL
Intervention: Desflurane (7.2% introduced, increased to 10.8%)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sevoflurane (2.2% introduced, increased to 3.3%)
Number of subjects: 20
Study: 8957037

Group type: EXPERIMENTAL
Intervention: Iron dextran MW 267,000 (group A)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Iron dextran MW 96,000 (group B)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both groups (A and B)
Number of subjects: 20
Study: 1325203

Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 5
Study: 3891178

Group type: EXPERIMENTAL
Intervention: High sodium bicarbonate dialysis
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: High sodium acetate dialysis
Number of subjects: 8

Group type: COMPARATOR
Intervention: Low sodium bicarbonate dialysis
Number of subjects: 8

Group type: COMPARATOR
Intervention: Low sodium acetate dialysis
Number of subjects: 8

Group type: COMPARATOR
Intervention: Bicarbonate dialysis
Number of subjects: 8
Study: 30126687

Group type: EXPERIMENTAL
Intervention: Selective laser melting (SLM)
Number of subjects: 36

Group type: COMPARATOR
Intervention: CAD-CAM milling
Number of subjects: 36

Group type: COMPARATOR
Intervention: Conventional casting
Number of subjects: 36
Study: 29603714

Group type: EXPERIMENTAL
Intervention: Instrumental variable (IV) method
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Anderson‐Rubin test
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mendelian randomization studies
Number of subjects: 0
Study: 26242466

Group type: EXPERIMENTAL
Intervention: Alfuzosin 10 mg/day for 3 weeks
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo for 3 weeks
Number of subjects: 70
Study: 25163440

Group type: EXPERIMENTAL
Intervention: saffron extract (30 mg/day)
Number of subjects: 68

Group type: COMPARATOR
Intervention: memantine (20 mg/day)
Number of subjects: 68
Study: 22151106

Group type: EXPERIMENTAL
Intervention: i-gel
Number of subjects: 120

Group type: COMPARATOR
Intervention: PLMA
Number of subjects: 120

Group type: COMPARATOR
Intervention: cLMA
Number of subjects: 120
Study: 19381108

Group type: EXPERIMENTAL
Intervention: Angiotensin II receptor blockers (ARBs)
Number of subjects: 108909

Group type: COMPARATOR
Intervention: Conventional treatment or placebo
Number of subjects: 108909

Group type: EXPERIMENTAL
Intervention: Combination therapy based on ARBs plus ACE inhibitors
Number of subjects: 108909
Study: 17449331

Group type: EXPERIMENTAL
Intervention: Epilepsy education program
Number of subjects: 783

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 783
Study: 15795533

Group type: EXPERIMENTAL
Intervention: Roxifiban (1 mg BID for 9 days)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Roxifiban (30 nmol/l free acid added to blood from roxifiban-treated subjects)
Number of subjects: 7
Study: 11985760

Group type: EXPERIMENTAL
Intervention: Surgical treatment (n=59)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Non-surgical treatment (n=53)
Number of subjects: 112
Study: 9793620

Group type: EXPERIMENTAL
Intervention: Levocabastine nasal spray and eyedrops
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Nedocromil nasal spray and eyedrops
Number of subjects: 102
Study: 7892820

Group type: EXPERIMENTAL
Intervention: Percutaneous transluminal coronary angioplasty (PTCA)
Number of subjects: 4120

Group type: COMPARATOR
Intervention: Coronary artery bypass grafting (CABG)
Number of subjects: 4120
Study: 2798542

Group type: EXPERIMENTAL
Intervention: Mecamylamine 2.5 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Mecamylamine 10 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Mecamylamine 20 mg
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Mecamylamine (all doses)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Mecamylamine (low doses)
Number of subjects: 8
Study: 871010

Group type: EXPERIMENTAL
Intervention: Independent study program (ISP)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Lecture discussion (LD) program
Number of subjects: 32
Study: 30670264

Group type: EXPERIMENTAL
Intervention: Low-power laser auriculotherapy (LA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Occlusal splints (OS)
Number of subjects: 0
Study: 28265719

Group type: EXPERIMENTAL
Intervention: Risedronate and vitamin K2
Number of subjects: 2922

Group type: COMPARATOR
Intervention: Risedronate alone
Number of subjects: 2922
Study: 25496265

Group type: EXPERIMENTAL
Intervention: 9% caloric intake from fructose added to milk
Number of subjects: 267

Group type: COMPARATOR
Intervention: 9% caloric intake from glucose added to milk
Number of subjects: 267

Group type: EXPERIMENTAL
Intervention: 18% caloric intake from high fructose corn syrup added to milk
Number of subjects: 267

Group type: COMPARATOR
Intervention: 18% caloric intake from sucrose added to milk
Number of subjects: 267
Study: 23438341

Group type: EXPERIMENTAL
Intervention: KAI-1678 (25 mg)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Lidocaine hydrochloride (700 mg)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 21052689

Group type: EXPERIMENTAL
Intervention: Intravenous amiodarone 1.25 mg/kg
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Intravenous amiodarone 2.5 mg/kg
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Intravenous amiodarone 5.0 mg/kg
Number of subjects: 32

Group type: COMPARATOR
Intervention: Glucose solution (control)
Number of subjects: 32
Study: 19125892

Group type: EXPERIMENTAL
Intervention: DAMET-2 program (experimental group)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 34
Study: 17233683

Group type: EXPERIMENTAL
Intervention: Multivitamin and mineral supplementation
Number of subjects: 763

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 763

Group type: EXPERIMENTAL
Intervention: Multivitamin and mineral supplementation (in subjects without dementia)
Number of subjects: 763
Study: 15605872

Group type: EXPERIMENTAL
Intervention: Motor unit number index (MUNIX) in normal subjects
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Motor unit number index (MUNIX) in ALS patients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Motor unit number index (MUNIX) in weaker muscles
Number of subjects: 0
Study: 11131823

Group type: EXPERIMENTAL
Intervention: Prior knowledge with uneven distribution of crossover features
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prior knowledge with even distribution of crossover features
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Slightly less uneven distribution of crossover features
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Knowledge benefits learning
Number of subjects: 0
Study: 9305486

Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg daily for 4 weeks
Number of subjects: 221

Group type: COMPARATOR
Intervention: Cimetidine 400 mg q.d.s. for 4 weeks
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg daily for an additional 4 weeks (total 8 weeks)
Number of subjects: 221
Study: 8370191

Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Amlodipine combined with beta blockers and/or long-acting nitrates
Number of subjects: 0
Study: 3554490

Group type: EXPERIMENTAL
Intervention: 4 mg propranolol intravenously twice daily
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: 10 mg propranolol intravenously twice daily
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo (in patients older than 60 years)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Propranolol (in patients older than 60 years)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo (in patients who had surgery on distal colon)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Propranolol (in patients who had surgery on distal colon)
Number of subjects: 39
Study: 30317269

Group type: EXPERIMENTAL
Intervention: HIFU treatment
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (surgically treated)
Number of subjects: 80
Study: 28059054

Group type: EXPERIMENTAL
Intervention: Families for Health
Number of subjects: 128

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 128
Study: 23489996

Group type: EXPERIMENTAL
Intervention: Definite atrial fibrillation
Number of subjects: 175
Study: 23436315

Group type: EXPERIMENTAL
Intervention: Liquid acetaminophen preparation (15 mg/kg)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Solid acetaminophen preparation (15 mg/kg)
Number of subjects: 15
Study: 21549065

Group type: EXPERIMENTAL
Intervention: sTREM-1 levels measured by ELISA
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Platelet count (PLT)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: SOFA score
Number of subjects: 32
Study: 19064624

Group type: EXPERIMENTAL
Intervention: artemether-lumefantrine
Number of subjects: 677

Group type: COMPARATOR
Intervention: chloroquine-sulfadoxine-pyrimethamine
Number of subjects: 677

Group type: EXPERIMENTAL
Intervention: artesunate-sulfadoxine-pyrimethamine
Number of subjects: 677

Group type: EXPERIMENTAL
Intervention: dihydroartemisinin-piperaquine
Number of subjects: 677
Study: 16626578

Group type: EXPERIMENTAL
Intervention: Enoxaparin (1 mg/kg subcutaneously, Q12 h, at least twice before CAG)
Number of subjects: 966

Group type: COMPARATOR
Intervention: UFH (25 mg iv before CAG with additional 65 mg iv if PCI indicated)
Number of subjects: 966

Group type: EXPERIMENTAL
Intervention: Enoxaparin
Number of subjects: 966

Group type: COMPARATOR
Intervention: UFH
Number of subjects: 966
Study: 14597864

Group type: EXPERIMENTAL
Intervention: Exercise electrocardiography
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Dipyridamole stress echo
Number of subjects: 71
Study: 10619579

Group type: EXPERIMENTAL
Intervention: Weight loss intervention (dietary counseling and group support)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 8840665

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 1721224

Group type: EXPERIMENTAL
Intervention: VVIR pacing
Number of subjects: 6

Group type: COMPARATOR
Intervention: VVI pacing
Number of subjects: 6
Study: 6805000

Group type: EXPERIMENTAL
Intervention: Digoxin and lithium carbonate
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo and lithium carbonate
Number of subjects: 28
Study: 29882634

Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT) for 11 weeks
Number of subjects: 67

Group type: COMPARATOR
Intervention: Control group (no change in physical exercise habits)
Number of subjects: 67
Study: 28656605

Group type: EXPERIMENTAL
Intervention: Somapacitan (0.02, 0.04, 0.08 and 0.16 mg/kg)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Norditropin® SimpleXx® (0.03 mg/kg)
Number of subjects: 32
Study: 26000501

Group type: EXPERIMENTAL
Intervention: Enhanced information and values clarification regarding prenatal genetic testing
Number of subjects: 710

Group type: COMPARATOR
Intervention: Usual care group (control)
Number of subjects: 710
Study: 22498012

Group type: EXPERIMENTAL
Intervention: Categorical involvement in 12-step activities
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oxford House condition
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care condition
Number of subjects: 0
Study: 21668279

Group type: EXPERIMENTAL
Intervention: Sealing materials (4 different types)
Number of subjects: 4
Study: 18711222

Group type: EXPERIMENTAL
Intervention: Chronic kidney disease (CKD)
Number of subjects: 3527

Group type: COMPARATOR
Intervention: GFR 45-59 ml/min/1.73 m² BSA
Number of subjects: 3527

Group type: COMPARATOR
Intervention: GFR <45 ml/min/1.73 m² BSA
Number of subjects: 3527
Study: 16428496

Group type: EXPERIMENTAL
Intervention: MOPPEBVCAD chemotherapy with limited radiotherapy
Number of subjects: 307

Group type: EXPERIMENTAL
Intervention: MOPPEBVCAD chemotherapy
Number of subjects: 307
Study: 15077576

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 11917836

Group type: EXPERIMENTAL
Intervention: Structured proforma for written communication with the ED
Number of subjects: 155

Group type: COMPARATOR
Intervention: Usual referral procedures (Control)
Number of subjects: 155
Study: 9894256

Group type: EXPERIMENTAL
Intervention: Combination therapy (Radiotherapy and endocrine therapy)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adjuvant endocrine therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Adjuvant radiotherapy and radical prostatectomy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Neoadjuvant endocrine therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Single-agent therapy (Radiotherapy and radical prostatectomy)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Endocrine therapy
Number of subjects: 0
Study: 7843425

Group type: EXPERIMENTAL
Intervention: Norethisterone acetate (NET) during the luteal phase of the previous cycle
Number of subjects: 80

Group type: COMPARATOR
Intervention: No norethisterone acetate (NET) during the luteal phase of the previous cycle (Control group)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Both groups received gonadotropin-releasing hormone agonist in follicular phase (flare-up) protocols
Number of subjects: 80
Study: 2196021

Group type: EXPERIMENTAL
Intervention: Digoxin
Number of subjects: 140

Group type: COMPARATOR
Intervention: No digoxin (Control)
Number of subjects: 140
Study: 26318

Group type: EXPERIMENTAL
Intervention: Presence of nasogastric tube
Number of subjects: 146

Group type: COMPARATOR
Intervention: Absence of nasogastric tube
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Inexperienced anesthetist
Number of subjects: 146

Group type: COMPARATOR
Intervention: Experienced anesthetist
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 146
Study: 7052188

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide, doxorubicin (Adriamycin) and 5‐fluorouracil
Number of subjects: 30

Group type: COMPARATOR
Intervention: Methotrexate, doxorubicin and 5‐fluorouracil with folinic acid rescue
Number of subjects: 30
Study: 30943454

Group type: EXPERIMENTAL
Intervention: Taped
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Braced
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: FRT
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control
Number of subjects: 12
Study: 29972712

Group type: EXPERIMENTAL
Intervention: Topical solution of 0.25% finasteride admixed with 3% minoxidil
Number of subjects: 40

Group type: COMPARATOR
Intervention: 3% minoxidil solution
Number of subjects: 40
Study: 26585431

Group type: EXPERIMENTAL
Intervention: High-dose oral prednisolone
Number of subjects: 92

Group type: COMPARATOR
Intervention: Medium-dose oral prednisolone
Number of subjects: 92
Study: 24645912

Group type: EXPERIMENTAL
Intervention: Hydrated foot (soaked in water)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-hydrated foot (control)
Number of subjects: 0
Study: 22452604

Group type: EXPERIMENTAL
Intervention: Probiotic multistrain treatment for 10 days
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Probiotic multistrain treatment
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Second line therapy for remaining positive patients
Number of subjects: 40
Study: 20101011

Group type: EXPERIMENTAL
Intervention: Adapted tai chi program (4 times 30 min/wk)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Cognition‐action program (2 times 30-45 min/wk)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 160
Study: 17625080

Group type: EXPERIMENTAL
Intervention: Sildenafil therapy
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 25
Study: 16040714

Group type: EXPERIMENTAL
Intervention: Intracoronary vitamin C with L-NMMA and dobutamine
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Intracoronary L-NMMA plus dobutamine
Number of subjects: 11

Group type: COMPARATOR
Intervention: Intravenous dobutamine alone
Number of subjects: 11
Study: 11788633

Group type: EXPERIMENTAL
Intervention: Phytoestrogens (PE) supplementation 150 mg/d
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 10086834

Group type: EXPERIMENTAL
Intervention: Tegretol (reference product)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Generic carbamazepine products
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cmax/AUCpart
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Partial AUC
Number of subjects: 0
Study: 7593378

Group type: EXPERIMENTAL
Intervention: Use of an extended-life disposable filter
Number of subjects: 12

Group type: COMPARATOR
Intervention: No filter
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Overall group comparison
Number of subjects: 12
Study: 2246375

Group type: EXPERIMENTAL
Intervention: Anxiety management training focused on coping with anger and hostility
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Operant self-control procedures
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 7364496

Group type: EXPERIMENTAL
Intervention: Aqueous D. pteronyssinus extract
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study: 31072967

Group type: EXPERIMENTAL
Intervention: Oxytocin (10 IU) administered intravenously within 15 seconds of birth
Number of subjects: 144

Group type: COMPARATOR
Intervention: Control group (oxytocin administered after clamping the umbilical cord 3 min after delivery)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Secondary outcomes
Number of subjects: 144
Study: 30367542

Group type: EXPERIMENTAL
Intervention: Positional change applied to patients in the experimental group (EG) with head of the bed elevated by 45-60°.
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control group (CG) in a supine position with head of the bed elevated to 15°.
Number of subjects: 200
Study: 28861888

Group type: EXPERIMENTAL
Intervention: Qingfei Mixture + azithromycin
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: azithromycin + Qingfei Mixture
Number of subjects: 46

Group type: COMPARATOR
Intervention: azithromycin
Number of subjects: 46

Group type: COMPARATOR
Intervention: Qingfei Mixture
Number of subjects: 46
Study: 25193142

Group type: EXPERIMENTAL
Intervention: PEERS intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 0
Study: 23833983

Group type: EXPERIMENTAL
Intervention: Functional connectivity observation using resting state fMRI in patients with sudden deafness
Number of subjects: 12

Group type: COMPARATOR
Intervention: Normal hearing group (control)
Number of subjects: 12
Study: 22086154

Group type: EXPERIMENTAL
Intervention: Bipolar transurethral vaporization (TUVP)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Standard transurethral resection of the prostate (TURP)
Number of subjects: 90
Study: 19594549

Group type: EXPERIMENTAL
Intervention: Skin Prick Test (SPT) with 7 mm egg white
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Skin Prick Test (SPT) with 9 mm egg white
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Specific IgE (sIgE) level of 1.5 KU/L for egg white
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Specific IgE (sIgE) level of 25 KU/L for egg white
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Skin Prick Tests (SPTs) with ovotransferrin and lysozyme
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Skin Prick Tests (SPTs) with yolk and ovalbumin
Number of subjects: 157
Study: 17467151

Group type: EXPERIMENTAL
Intervention: Telaprevir (VX-950)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 15173716

Group type: EXPERIMENTAL
Intervention: On-pump beating heart surgery
Number of subjects: 37

Group type: COMPARATOR
Intervention: Off-pump coronary bypass surgery
Number of subjects: 37
Study: 11561142

Group type: EXPERIMENTAL
Intervention: Cefepime
Number of subjects: 40

Group type: COMPARATOR
Intervention: Ceftriaxone plus amikacin
Number of subjects: 40
Study: 9250235

Group type: EXPERIMENTAL
Intervention: Metered-dose inhaler (MDI) with spacer devices
Number of subjects: 507

Group type: COMPARATOR
Intervention: Wet nebulizer
Number of subjects: 507
Study: 7695059

Group type: EXPERIMENTAL
Intervention: Mechanical ventilation homes
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (unchanged conditions)
Number of subjects: 30
Study: 2888801

Group type: EXPERIMENTAL
Intervention: Metronidazole (M) 1.35 g/day
Number of subjects: 46

Group type: COMPARATOR
Intervention: Sulfasalazine (S) 4.5 g/day
Number of subjects: 46
Study: 31928120

Group type: EXPERIMENTAL
Intervention: Symax hip stem
Number of subjects: 45
Study: 31375874

Group type: EXPERIMENTAL
Intervention: Milk powder fortified with vitamin D 400 IU plus calcium 600 mg (Ca6D)
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: Milk powder fortified with vitamin D 400 IU plus calcium 300 mg (Ca3D)
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: Milk powder fortified with vitamin D 400 IU plus calcium 900 mg (Ca9D)
Number of subjects: 232

Group type: COMPARATOR
Intervention: Control group maintaining habitual diet
Number of subjects: 232
Study: 29045514

Group type: EXPERIMENTAL
Intervention: ALK inhibitor (ALKi)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: anti-PD-1 antibody (Ab)
Number of subjects: 0
Study: 25728208

Group type: EXPERIMENTAL
Intervention: Fidaxomicin
Number of subjects: 134

Group type: COMPARATOR
Intervention: Metronidazole and/or Vancomycin
Number of subjects: 134
Study: 23793805

Group type: EXPERIMENTAL
Intervention: Laparoscopy-assisted distal gastrectomy (LADG)
Number of subjects: 164

Group type: COMPARATOR
Intervention: Open distal gastrectomy (ODG)
Number of subjects: 164
Study: 21518978

Group type: EXPERIMENTAL
Intervention: Bilateral catheter-based renal denervation
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 50
Study: 19837434

Group type: EXPERIMENTAL
Intervention: 50 mg sildenafil for 4 weeks
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 16960937

Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) treatment for 28 weeks
Number of subjects: 36

Group type: COMPARATOR
Intervention: Healthy controls (no treatment)
Number of subjects: 36